KMM-1Homo sapiens (Human)Cancer cell line
Also known as: KMM1
Quick Overview
Human multiple myeloma cell line with B-cell origin, used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_2981 |
---|---|
Species | Homo sapiens (Human) |
Donor Information
Age | 62 |
---|---|
Age Category | Adult |
Sex | Male |
Race | asian |
Disease Information
Disease | Multiple myeloma |
---|---|
Lineage | Lymphoid |
Subtype | Plasma Cell Myeloma |
OncoTree Code | PCM |
DepMap Information
Source Type | HSRRB |
---|---|
Source ID | ACH-000889_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | TP53 | p.Ser241Phe (c.722C>T) | Unspecified | - | PubMed=23851445, PubMed=17260012 |
MutationSimple | NRAS | p.Gly13Asp (c.38G>A) | Unspecified | - | PubMed=32014918 |
MutationSimple | KRAS | p.Val9Ile (c.25G>A) | Heterozygous | - | Unknown |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Sirota M., Wiita A.P.
Leukemia 34:2754-2765(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Pellat-Deceunynck C.
J. Hematol. Oncol. 11:137.1-137.13(2018).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
Cytometry A 87:285-288(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F.
Eur. J. Haematol. 91:504-513(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Pellat-Deceunynck C.
Haematologica 96:574-582(2011).
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.
Fabris S., Lambertenghi-Deliliers G., Neri A.
BMC Med. Genomics 1:37.1-37.9(2008).
Characterization of MYC translocations in multiple myeloma cell lines.
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Stewart A.K., Carpten J.D., Bergsagel P.L.
Cancer Cell 12:131-144(2007).
Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Lambertenghi-Deliliers G., Bertoni F., Neri A.
Genes Chromosomes Cancer 46:226-238(2007).
Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.
Taniwaki M., Inazawa J.
Am. J. Pathol. 165:71-81(2004).
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Kuehl W.M., Bergsagel P.L.
Blood 97:729-736(2001).
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Drexler H.G., Matsuo Y.
Leuk. Res. 24:681-703(2000).
Screening the p53 status of human cell lines using a yeast functional assay.
Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Mol. Carcinog. 19:243-253(1997).
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Kuehl W.M.
Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
Establishment of five human myeloma cell lines.";
Yawata Y., Kimoto T.
In Vitro Cell. Dev. Biol. 25:723-729(1989).
Establishment and characterization of five human myeloma cell lines.
Ohtsuki T., Yawata Y., Namba M.
Hum. Cell 2:297-303(1989).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
Multiple myeloma cell lines.";
Jernberg-Wiklund H., Nilsson K.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).